Ocular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced new data to be presented from its most recent Phase 3 study evaluating the efficacy and safety of DEXTENZA™ (dexamethasone insert, 0.4mg) for intracanalicular use, for the treatment of ocular pain and inflammation following cataract surgery, at the upcom